Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120358) titled 'An exploratory clinical study on pierced-therapy +/- radiotherapy for refractory gliomas' on March 12.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Fudan University Shanghai Cancer Center
Condition:
Non-small cell lung cancer
Intervention:
Recurrent and high-grade gliomas group:Vebreltinib combine with Bevacizumab and Temozolimide. Vebreltinib 200mg bid, Bevacizumab 3-5mg/kg, q2w and Temozolimide150mg/m^2 (5/28). radiotherapy is allowed,and the dosage and frequency are decided by investigator.
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-0...